Radiation Dose-Volume Effects in the Heart

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3 SUPPL., 2010, Pages

  Gagliardi, Giovanna ^a   Constine, Louis S ^b   Moiseenko, Vitali ^c   Correa, Candace ^d   Pierce, Lori J ^d   Allen, Aaron M ^e   Marks, Lawrence B ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MA Rabin Medical Center Petach Tikvah   (Israel)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Dose volume predictors; Esophagus cancer; Lymphoma; NTCP; Radiation heart disease

Indexed keywords

BREAST CANCER; CARDIAC TOXICITY; DOSE-VOLUME; DOXORUBICIN; ESOPHAGUS CANCER; HEART DISEASE; RADIATION DOSE; RADIATION-INDUCED;

CARDIOLOGY; HEART; ONCOLOGY; RADIATION EFFECTS;

RADIOTHERAPY;

ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BIOLOGICAL MODEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HEART DISEASE; HEART INJURY; HEART VALVE STENOSIS; HEART VOLUME; HODGKIN DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MATHEMATICAL MODEL; MEDIASTINUM TUMOR; MITRAL VALVE REGURGITATION; MORTALITY; PERICARDIAL EFFUSION; PERICARDITIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RADIATION INJURY; RADIATION RESPONSE; VALVULAR HEART DISEASE;

BREAST NEOPLASMS; FEMALE; HEART; HEART DISEASES; HODGKIN DISEASE; HUMANS; MALE; MODELS, BIOLOGICAL; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RISK FACTORS;

EID: 76449107176     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.093     Document Type: Article

References (66)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trials. Lancet 366 (2005) 2087-2106
2. Aleman B.M., Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
3. Carmel R.J., and Kaplan H.S. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumour eradication, and complications. Cancer 37 (1976) 2813-2825
4. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-Year results of the British Columbia randomized trial. J Natl Cancer Inst 97 (2005) 116-126
5. Høst H., Brennhovd I., and Loeb M. Postoperative radiotherapy in breast cancer - long term results from the Oslo study. Int J Radiat Oncol Biol Phys 12 (1986) 727-732
6. Paszat L.F., Vallis K.A., Benk V.M., et al. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother Oncol 82 (2007) 294-300
7. Darby S.C., McGale P., Taylor C.W., et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6 (2005) 557-565
8. Paszat L.F., Mackillop W.J., Groome P.A., et al. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 43 (1999) 755-761
9. Højris I., Overgaard M., Christensen J.J., et al. Morbidity and mortality of ischemic heart disease in high-risk breast cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomized trials. Lancet 354 (1999) 1425-1430
10. Harris E.E., Correa C., Hwang W.T., et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24 (2006) 4100-4106
11. Correa C.R., Litt H.I., Hwang W.T., et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25 (2007) 3031-3037
12. Hooning M.J., Botma A., Aleman B.M., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99 (2007) 365-375
13. Borger J.H., Hooning M.J., Boersma L.J., et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: The role of irradiated heart volume. Int J Radiat Oncol Biol Phys 69 (2007) 1131-1138
14. Prosnitz R.G., Hubbs J.L., Evans E.S., et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: Analysis of data 3 to 6 years after treatment. Cancer 110 (2007) 1840-1850
15. Gyenes G., Fornander T., Carlens P., et al. Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 28 (1994) 1235-1241
16. Hancock S.L., Donaldsson S.S., and Hoppe R.T. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11 (1993) 1208-1215
17. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodkgin's disease. J Am Med Assoc 270 (1993) 1949-1955
18. Swerdlow A.J., Higgins C.D., Smith P., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 99 (2007) 206-214
19. Boivin J.F., Hutchison G.B., Lubin J.H., et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69 (1992) 1241-1247
20. Adams M.J., Lipsitz S.R., Colan S.D., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22 (2004) 3139-3148
21. Glanzmann C., Huguenin P., Lutolf U.M., et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 30 (1994) 43-54
22. Lund M.B., Ihlen H., Voss B.M., et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: An echocardiographic study. Heart 75 (1996) 591-595
23. Heidenreich P., Hancock S., Lee B., Mariscal C., and Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42 (2003) 743-749
24. Jagsi R., Moran J.M., Kessler M.L., et al. Respiratory motion of the heart and positional reproducibility under active breathing control. Int J Radiat Oncol Biol Phys 68 (2007) 253-258
25. Gagliardi G., Lax I., Ottolenghi A., et al. Long-term cardiac mortality after radiotherapy of breast cancer - application of the relative seriality model. Br J Radiol 69 (1996) 839-846
26. Martel M.K., Sahijdak W.M., Ten Haken R.K., et al. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys 40 (1998) 155-161
27. Wei X., Liu H.H., Tucker S.L., et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70 (2008) 707-714
28. Das S.K., Baydusch A.H., Zhou S., et al. Predicting radiotherapy-induced cardiac perfusion defects. Med Phys 32 (2005) 19-27
29. Nieder C., Schill S., Kneschaurek, et al. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2 (2007) 20
30. Taylor C.W., Nisbet A., McGale P., et al. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 69 (2007) 1484-1495
31. Taylor C.W., Povall J.M., McGale P., et al. Cardiac dose from contemporary tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys 72 (2008) 501-507
32. Giordano S.H., Kuo Y., Freeman J.L., et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97 (2005) 419-424
33. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
34. Grundy S.M., Pasternak R., Greenland P., et al. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 34 (1999) 1348-1359
35. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J Am Med Assoc 297 (2007) 611-619
36. Hooning M.J., Aleman B.M., van Rosmalen A.J., et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 64 (2007) 1081-1091
37. King V., Constine L.S., Clark D., et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 36 (1996) 881-889
38. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
39. Ryberg M., Nielsen D., Skovsgaard T., et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16 (1998) 3502-3508
40. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 (2006) 2474-2481
41. Doyle J.J., Neugut A.I., Jacobson J.S., et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23 (2005) 8597-8605
42. Gianni L., Dombernowsky P., Sledge, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer. Ann Oncol 12 (2001) 1067-1073
43. Shapiro C.L., Hardenbergh P.H., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16 (1998) 3493-3501
44. Halyard M.Y., Pisansky T.M., Dueck A.C., et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 27 16 (2009) 2638-2644
45. Aleman B.M., van den Belt-Dusebout A.W., De Bruin M.L., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 (2007) 1878-1886
46. Stewart J.R., and Fajardo L.F. Dose response in human and experimental radiation-induced heart disease. Application of the nominal standard dose (NSD) concept. Radiology 99 (1971) 403-408
47. Lyman J.T. Complication probabilities as assessed from dose-volume histograms. Rad Res Suppl 8 (1985) S13-S19
48. Rutqvist L.E., Lax I., Fornander T., and Johansson H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22 (1992) 887-896
49. Källman P., Ågren A., and Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol 62 (1992) 249-262
50. Gagliardi G., Lax I., and Rutqvist L.E. Partial irradiation of the heart. Semin Radiat Oncol 7 (2001) 224-233
51. Eriksson F., Gagliardi G., Liedberg A., et al. Long-term cardiac mortality following radiation therapy for Hodgkin's disease: Analysis with the relative seriality model. Radiother Oncol 55 (2000) 153-162
52. Carr Z.A., Land C.E., Kleinerman R.A., et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys 61 (2005) 842-850
53. Hurkmans C.W., Borger J.H., Bos L.J., et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 55 (2000) 145-151
54. Marks L.B., Yu X., Prosnitz R.G., et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63 (2005) 214-223
55. Polednik M., Abo Madyan Y., Schenider F., et al. Evaluation of calculation algorithms implemented in different commercial planning systems on an anthropomorphic breast phantom using film dosimetry. Strahlenther Onkol 183 (2007) 667-672
56. Gagliardi G., Lax I., Söderström S., et al. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol 46 (1998) 63-71
57. Louwe R.J., Wendling M., van Herk M.B., and Mijnheer B.J. Three-dimensional dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys 34 (2007) 1354-1363
58. Executive Summary of the Third Report of the National cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 285 (2001) 2486-2497
59. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 Update. J Am Coll Cardiol 49 (2007) 1230-1250
60. Jones L.W., Haykowsky M.J., Swartz J.J., et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50 (2007) 1435-1441
61. Dautzenberg B., Arriagada R., Chammard A.B., et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 86 (1999) 265-273
62. Lally B.E., Detterbeck F.C., Geiger A.M., et al. The risk from heart disease in patients with non small cell lung cancer who receive postoperative radiotherapy. Analysis of the Surveillance, Epidemiology, and End Results Database. Cancer (2007)
63. Van Luijk P., Faber H., Meertens H., et al. The impact of heart irradiation on dose-volume effects in the rat lung. Int J Radiat Oncol Biol Phys 69 (2007) 552-559
64. LENT-SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 31 1049 (1995) 1091
65. Cosset J.M., Henry-Amar M., and Meerwaldt J.H. Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol S2 (1991) 77-82
66. Burman C., Kutcher G.J., Emami B., et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21 (1991) 123-135